Treatment effect validation – propensity score matching


A (n = 16390)

B (n = 1282)

C (n = 474)

D (n = 278)

Treatment effect validation – propensity score matching + adjusted

A (n = 16390)

B (n = 1282)

C (n = 474)

D (n = 278)

Treatment effect validation – adjusted

**Adjusted**

White ■ South Asian ■ Black ■ Other/Mixed

Overall population (n=48,686)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=3,651)

3–5 mmol/mol (n=4,834)

0–3 mmol/mol (n=14,877)

Predicted HbA1c benefit on GLP1−RA

0–3 mmol/mol (n=15,429)

3–5 mmol/mol (n=6,363)

>5 mmol/mol (n=3,532)

Average treatment effect

Average treatment effect (mmol/mol)

Treatment effect heterogeneity

A
Ethnicity: white

B
Ethnicity: south asian

C
Ethnicity: black

D
Ethnicity: other/mixed

Favours SGLT2i   Favours GLP1–RA